Pre-stroke aspirin use was associated with a 32% higher likelihood of favorable functional outcome at 3 months (OR 1.32) and a 30% reduction in infarct volume compared to nonuse in patients with first-ever ischemic stroke.
Observational (n=5,700)
Yes
Acute first-ever ischemic stroke (n=5,700)
Pre-stroke aspirin vs No pre-stroke aspirin
Favorable functional outcome at 3 months (mRS 0-2) — OR 1.32 (1.13-1.54), p=<0.001
Effect estimate: OR 1.32 (95% CI 1.13-1.54)
Absolute Event Rate: 71.3% vs 67.8%
p-value: p=<0.001
Objective We investigated (1) the associations of pre‐stroke aspirin use with thrombus burden, infarct volume, hemorrhagic transformation, early neurological deterioration (END), and functional outcome, and (2) whether stroke subtypes modify these associations in first‐ever ischemic stroke. Methods This multicenter magnetic resonance imaging (MRI)‐based study included 5,700 consecutive patients with acute first‐ever ischemic stroke, who did not undergo intravenous thrombolysis or endovascular thrombectomy, from May 2011 through February 2014. Propensity score‐based augmented inverse probability weighting was performed to estimate adjusted effects of pre‐stroke aspirin use. Results The mean age was 67 years (41% women), and 15.9% (n = 907) were taking aspirin before stroke. Pre‐stroke aspirin use (vs nonuse) was significantly related to a reduced infarct volume (by 30%), particularly in large artery atherosclerosis stroke (by 45%). In cardioembolic stroke, pre‐stroke aspirin use was associated with a ~50% lower incidence of END (adjusted difference = −5.4%, 95% confidence interval CI = −8.9 to −1.9). Thus, pre‐stroke aspirin use was associated with ~30% higher likelihood of favorable outcome (3‐month modified Rankin Scale score < 3), particularly in large artery atherosclerosis stroke and cardioembolic stroke (adjusted difference = 7.2%, 95% CI = 1.8 to 12.5 and adjusted difference = 6.4%, 95% CI = 1.7 to 11.1, respectively). Pre‐stroke aspirin use (vs nonuse) was associated with 85% less frequent cerebral thrombus‐related susceptibility vessel sign (SVS) in large artery atherosclerosis stroke (adjusted difference = −1.4%, 95% CI = −2.1 to −0.8, p < 0.001) and was associated with ~40% lower SVS volumes, particularly in cardioembolic stroke (adjusted difference = −0.16 cm 3 , 95% CI = −0.29 to −0.02, p = 0.03). Moreover, pre‐stroke aspirin use was not significantly associated with hemorrhagic transformation (adjusted difference = −1.1%, p = 0.09). Interpretation Pre‐stroke aspirin use associates with improved functional independence in patients with first‐ever ischemic large arterial stroke by reducing infarct volume and/or END, likely by decreasing thrombus burden, without increased risk of hemorrhagic transformation. ANN NEUROL 2021;90:763–776
Building similarity graph...
Analyzing shared references across papers
Loading...
Wi‐Sun Ryu
E Ink (South Korea)
Dawid Schellingerhout
The University of Texas MD Anderson Cancer Center
Keun‐Sik Hong
University College Dublin
Annals of Neurology
Harvard University
Massachusetts General Hospital
The University of Texas MD Anderson Cancer Center
Building similarity graph...
Analyzing shared references across papers
Loading...
Ryu et al. (Sat,) conducted a observational in Acute first-ever ischemic stroke (n=5,700). Pre-stroke aspirin vs. No pre-stroke aspirin was evaluated on Favorable functional outcome at 3 months (mRS 0-2) (OR 1.32, 95% CI 1.13-1.54, p=<0.001). Pre-stroke aspirin use was associated with a 32% higher likelihood of favorable functional outcome at 3 months (OR 1.32) and a 30% reduction in infarct volume compared to nonuse in patients with first-ever ischemic stroke.
synapsesocial.com/papers/6a129848c031bb6829a6f021 — DOI: https://doi.org/10.1002/ana.26219